ES2524916T3 - Compuestos heterocíclicos de ácido borónico - Google Patents
Compuestos heterocíclicos de ácido borónico Download PDFInfo
- Publication number
- ES2524916T3 ES2524916T3 ES04810839.3T ES04810839T ES2524916T3 ES 2524916 T3 ES2524916 T3 ES 2524916T3 ES 04810839 T ES04810839 T ES 04810839T ES 2524916 T3 ES2524916 T3 ES 2524916T3
- Authority
- ES
- Spain
- Prior art keywords
- formula
- alkyl
- compound
- majority
- minority
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 Heterocyclic boronic acid compounds Chemical class 0.000 title abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 31
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 125000005620 boronic acid group Chemical group 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 abstract description 18
- 125000004122 cyclic group Chemical group 0.000 abstract description 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 5
- 239000001257 hydrogen Substances 0.000 abstract description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract description 4
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 abstract description 4
- 150000004677 hydrates Chemical class 0.000 abstract description 4
- 239000012453 solvate Substances 0.000 abstract description 4
- 239000007864 aqueous solution Substances 0.000 abstract description 3
- 229910052736 halogen Inorganic materials 0.000 abstract description 3
- 239000007788 liquid Substances 0.000 abstract description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 abstract 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 2
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000006239 protecting group Chemical group 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 12
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical class NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 102000004860 Dipeptidases Human genes 0.000 description 1
- 108090001081 Dipeptidases Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical group 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001576 beta-amino acids Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229910052500 inorganic mineral Chemical class 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011707 mineral Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
Abstract
Compuesto de fórmula (I):**Fórmula** que incluye sus isómeros cíclicos que presentan la fórmula**Fórmula** sus estereoisómeros, sus solvatos, sus hidratos y sus sales farmacéuticamente aceptables, en la que: n es 1; X es CH2; Z es H; R1 y R2 independiente o conjuntamente son -OH; un hidroxilo portador de un grupo protector de ácido 20 borónico; o un grupo que puede hidrolizarse a un grupo hidroxilo en una solución acuosa a pH fisiológico o en los líquidos biológicos; R3 y R4 son hidrógeno y R5 es:**Fórmula** en las que R20 es hidrógeno, alquilo(C1-8), alquil(C1-6)carbonilo, dialquil(C1-6)aminocarbonilo, cicloalquil(C3-8)carbonilo; bencilo, benzoílo, alquil(C1-6)oxicarbonilo, aralquiloxicarbonilo, piridinilo, pirimidinilo, fenilo, tiazolilo sustituido en fenilo, fenilaminocarbonilo, alquilsulfonilo o fenilsulfonilo; en el que los grupos bencilo, benzoílo, piridinilo, pirimidinilo, fenilo, fenilaminocarbonilo, alquilsulfonilo y fenilsulfonilo están opcionalmente monosustituidos o independientemente disustituidos con R12; R12 es halógeno, trifluorometilo, ciano, nitro, alquilo(C1 -6 ), alcoxi(C1-6), cicloalquilo, carboxi, acetamido, hidroxi, hidroxialquilo(C1-6), hidroximetilo, trifluorometoxi, sulfamoílo, carbamoílo, sulfonamido, alquilsulfonilo, fenilsulfonilo, arilo, o heteroarilo; en el que los grupos arilo y heteroarilo están opcionalmente monosustituidos o independientemente plurisustituidos con R7; R7 es halógeno, alquilo(C1-10), alcoxi(C1-10), alquil(C1-10)amino, dialquil(C1-10) amino, bencilo, benciloxi, hidroxialquilo(C1-6), hidroximetilo, nitro, trifluorometilo, trifluorometoxi, trifluorometiltio, N-hidroxiamino, ciano, carboxi, acetamido, hidroxi, sulfamoílo, sulfonamido, carbamoílo
Description
E04810839
26-11-2014
obesos recuperan finalmente su peso. Unos medios eficaces para afianzar y/o mantener la pérdida de peso son el principal reto en el tratamiento de la obesidad hoy en día.
Por consiguiente, existe una necesidad de compuestos que sean útiles para la inhibición de DPP-IV sin suprimir el 5 sistema inmunitario.
Se ha demostrado que varios compuestos inhiben la DPP-IV, pero todos ellos tienen limitaciones en relación con la potencia, estabilidad, selectividad, toxicidad, y/o propiedades farmacodinámicas. Dichos compuestos se han descrito, por ejemplo, en los documentos WO 98/19998, WO 00/34241, la patente US nº 6.124.305 (Novartis AG), y
10 el documento WO 99/38501 (Trustees of Tufts University) y el documento WO 95/15309.
La presente invención proporciona inhibidores de DPP-IV que son eficaces en el tratamiento de afecciones que
15 pueden ser reguladas o normalizadas por la inhibición de DPP-IV. Más particularmente, la invención se refiere a heterociclos que contienen ácido borónico y sus derivados que inhiben la DPP-IV, y a procedimientos para preparar dichos compuestos. Además, la invención proporciona composiciones farmacéuticas que comprenden compuestos de la invención, y combinaciones de los mismos, incluidos uno o más de otros tipos de agentes antidiabéticos; procedimientos para inhibir la DPP-IV que comprenden la administración a un paciente que necesita
20 dicho tratamiento de una cantidad terapéuticamente eficaz del mismo; y compuestos para utilización como producto farmacéutico, y su utilización en un procedimiento para la preparación de un medicamento para el tratamiento de una afección que se regula o normaliza por inhibición de la DPP-IV.
25 La figura 1 muestra la dependencia del pH del porcentaje de formas isómeras lineales y cíclicas presentes en solución acuosa de un compuesto de la invención.
30 La presente invención proporciona compuestos de fórmula I:
35 incluidos los isómeros cíclicos de los mismos de fórmula
estereoisómeros, solvatos, hidratos y sales farmacéuticamente aceptables de lo mismos, en los que: 40 nes1;
X es CH2;
Z es H;
E04810839
26-11-2014
o una mezcla de los mismos.
5 En otro aspecto todavía, la invención proporciona inhibidores de ácido borónico de dipeptidil peptidasa-IV con una constante de inhibición de 10 micromolar o menos para la dipeptidil peptidasa-IV. Dichos inhibidores comprenden una boroprolina (incluidas boropirrolidinas, boropiperidinas y boroazepanes) unida a un aminoácido a través de un enlace amida. El aminoácido puede ser un beta-aminoácido (incluidas formas cíclicas, tales como un N-cicloalquilalfa-aminoácido, un N-heterociclil-alfa-aminoácido, un alfa-aminoácido cíclico que tiene al menos un sustituyente en
10 el anillo de ácido alfa-amino o que tiene un anillo distinto de pirrolidina o glicina N-sustituida. En algunas formas de realización, el inhibidor de ácido borónico es de fórmula I:
15 incluidos los isómeros cíclicos de los mismos de fórmula
los estereoisómeros, solvatos, hidratos y sales farmacéuticamente aceptables de los mismos, en los que: 20
n es 1;
X es CH2;
25 ZesH;
R1 y R2 independientemente o juntos son hidrógeno; un grupo protector de ácido borónico, o un grupo que puede
hidrolizarse a un grupo hidroxilo en una solución acuosa a pH fisiológico o en líquidos biológicos;
30 R3 y R4 son hidrógeno y R5 es:
5
10
15
20
25
30
35
40
45
50
55 E04810839
26-11-2014
con una amina de fórmula: R5-NH2; desprotegiendo opcionalmente el éster de ácido borónico; y recuperando el compuesto resultante como un ácido libre o como una sal de adición de ácido; en la que L es un grupo saliente. R1, R2, R3, R4, Ri, Rii, n, X, y Z se definen en la presente memoria. CRiRii no está. Las formas de realización preferidas son aquellas en las que R3 y R4 son hidrógeno, L es halógeno, incluidos, pero no limitados a Cl, y R5-NH2 es ciclopentilamina.
Los compuestos de la invención se pueden preparar en forma de sales farmacéuticamente aceptables, especialmente sales de adición de ácido, incluidas las sales de ácidos orgánicos y de ácidos minerales. Los ejemplos de dichas sales comprenden sales de ácidos orgánicos tales como ácido fórmico, ácido fumárico, ácido acético, ácido propiónico, ácido glicólico, ácido láctico, ácido pirúvico, ácido oxálico, ácido succínico, ácido málico, ácido tartárico, ácido cítrico, ácido benzoico, ácido salicílico y similares. Las sales de adición de ácido inorgánicas adecuadas comprenden sales de ácido clorhídrico, bromhídrico, sulfúrico y fosfórico y similares. Otros ejemplos de sales de adición de ácidos inorgánicos u orgánicos farmacéuticamente aceptables comprenden las sales farmacéuticamente aceptables enumeradas en Journal of Pharmaceutical Science, 66, 2 (1977) que son conocidas por el experto en la materia.
Las sales de adición de ácidos pueden obtenerse como los productos directos de síntesis de compuestos. Alternativamente, la base libre puede disolverse en un disolvente adecuado que contenga el ácido apropiado, y la sal aislada por evaporación del disolvente o si no separando la sal y el disolvente.
Los compuestos de la presente invención pueden formar solvatos con disolventes normales de bajo peso molecular, incluida el agua para producir hidratos, utilizando procedimientos conocidos por el experto en la materia.
Debe apreciarse que la invención se extiende a todas las formas estereoisómeras de los compuestos reivindicados, incluidos los enantiómeros y diastereómeros, así como los racematos.
Otro aspecto de la invención proporciona procedimientos y utilizaciones para los compuestos de la invención. En un planteamiento, los compuestos de la invención se pueden administrar a un individuo que padece una enfermedad o afección en la que interviene una amino-dipeptidasa de escisión de post-prolina/alanina. En esta forma de realización, se administra al paciente una cantidad del compuesto de la invención eficaz en la reducción de la actividad de amino-dipeptidasa de escisión de la post-prolina/alanina y, de ese modo, reducir o aliviar los síntomas de la enfermedad o afección. En algunas formas de realización, el compuesto administrado reduce la actividad de DPP-IV. En algunas formas de realización, la enfermedad o afección se selecciona del grupo formado por diabetes, complicaciones diabéticas, hiperglucemia, síndrome X, hiperinsulinemia, obesidad, aterosclerosis y enfermedades relacionadas. Los compuestos de la invención que deben administrarse pueden ser uno o más de los compuestos de ácido borónico de la invención, que pueden formularse de cualquier manera descrita en la presente memoria, incluida la combinación con "otro(s) tipo(s) de agente(s) terapéutico(s)" identificado(s) a continuación”.
Otras formas de realización ilustrativas de los procedimientos de la invención están representadas por:
Procedimientos para la inhibición de DPP-IV que comprende administrar a un mamífero que necesita dicho tratamiento una cantidad terapéuticamente eficaz de un compuesto de la invención o de una sal de adición de ácido farmacéuticamente aceptable del mismo;
Procedimientos para el tratamiento de afecciones en las que interviene DPP-IV que comprende administrar a un mamífero que necesita dicho tratamiento una cantidad terapéuticamente eficaz de un compuesto de la invención o de una sal de adición de ácido farmacéuticamente aceptable del mismo;
Procedimientos para el control del tratamiento o prevención de la diabetes que comprende la administración a un paciente de una cantidad eficaz de un compuesto de la invención;
Procedimientos para el tratamiento, el control o la prevención de la diabetes mellitus dependiente de insulina (Tipo I) y/o no dependiente de insulina (Tipo 2) en un paciente mamífero que necesita dicho tratamiento, que comprende administrar al paciente una cantidad terapéuticamente eficaz de un compuesto de la invención;
E04810839
26-11-2014
MHz, CD3OD) δ 4,12 (m, 3H), 3,76 (m, 1H), 3,54 (m, 3H), 3,41 (m, 2H), 3,26 (m, 1H) , 2,55 (m, 1H), 2,28 (m, 1H), 2,05 (m, 3H), 1,74 (m, 1H).MS m/z (intensidad relativa) 241 (M) (27), 224 (100), 209 (73), 155 (47).
5 Utilizando los procedimientos ilustrados anteriormente se prepararon y caracterizaron los siguientes compuestos en la tabla, utilizando cromatografía de líquidos-espectroscopia de masas (LC-MS).
Tabla 10
- Compuesto nº
- Serie Estructura LC-MS
- 22
-
A
imagen32 255 (M+1)(13), 237 (100)
- 23
-
A
imagen33 227 (M+1)(10), 209 (100)
- 24
-
A
imagen34 229 (M+1)(18), 211 (100)
- 25
-
A
imagen35 215 (M+1)(12), 197 (100)
- 26
-
A
imagen36 263 (M+1)(5), 245 (100)
- 27
-
A
imagen37 277 (M+1)(4), 259 (100)
- 28
-
A
imagen38 283 (M+1)(22), 265 (100)
- 29
-
A
imagen39 277 (M+1)(5), 259 (100)
- 30
-
A
imagen40 283 (M+1)(21), 265 (100)
E04810839
26-11-2014 E04810839
- 31
-
A
imagen41 269 (M+1)(16), 251 (100)
- 32
-
A
imagen42 763 (6), 382 (M+1)(100)
- 33
-
A
imagen43 284 (M+1)(19), 266(100)
- 34
-
A
imagen44 651 (28), 326 (M+1)(57), 308 (100)
- 35
-
A
imagen45 691 (22), 346 (M+1)(100), 328 (86)
- 36
-
A
imagen46 703 (28), 352 (M+1)(18), 334 (100)
- 37
-
A
imagen47 691 (49), 346 (M+1)(14), 328(100)
- 38
-
A
imagen48 703 (27), 352 (M+1)(3), 334 (100)
- 39
-
A
imagen49 651 (48), 326(13), 308 (100)
- 40
-
A
imagen50 382 (M+1)(100), 364 (7)
- 41
-
A
imagen51 332 (M+1)(100), 314 (10)
26-11-2014 E04810839
- 42
-
A
imagen52 531 (15), 266 (M-17)(100)
- 43
-
A
imagen53 271 (M+1)(100), 253 (16)
- 44
-
A
imagen54 270 (M+1)(100), 252 (17)
- 45
-
A
imagen55 731 (42), 366 (M+1)(100), 348 (43)
- 46
-
A
imagen56 791 (12), 396 (M+1)
- 47
-
A
imagen57 721 (10), 361 (M+1)(100)
- 48
-
A
imagen58 285 (M+1)(100), 267 (12)
- 49
-
A
imagen59 595 (48), 298 (M+1)(100), 280 (80)
- 50
-
A
imagen60 679 (29), 340 (100)
- 51
-
A
imagen61 719 (92), 360 (M+1)(65), 342 (100)
- 52
-
A
imagen62 791 (35), 396 (M+1)(100), 378 (14)
26-11-2014 E04810839
- 53
-
A
imagen63 595 (89), 298 (M+1)(44), 280 (100)
- 54
-
A
imagen64 719 (72), 360 (M+1)(40), 342 (100)
- 55
-
A
imagen65 731 (100), 366 (M+1)(34), 348 (86)
- 56
-
A
imagen66 340 (M+1)(5), 322 (100), 304(18)
- 57
-
A
imagen67 731 (100), 366 (M+1)(52), 348 (94)
- 58
-
A
imagen68 773 (33), 396 (M+1)(100), 378 (16)
- 59
-
A
imagen69 595 (93), 298 (M+1)(26), 280 (100)
- 60
-
A
imagen70 679 (100), 340 (98), 322 (70)
- 61
-
A
imagen71 346 (M+1)(100), 328 (12)
- 62
-
B
imagen72 249(M-17)mayoritario, 267(M+1)minoritario
- 63
-
B
imagen73 289(M+1)minoritario, 271 (M17)mayoritario
26-11-2014 E04810839
- 64
-
B
imagen74 289(M+1)minoritario, 271 (M17)mayoritario
- 65
-
B
imagen75 213(M-17), 425(2M+1)
- 66
-
B
imagen76 282(M-17) mayoritario
- 67
-
imagen77 257(M-17)mayoritario, 275(M+1)minoritario
- 68
-
B
imagen78 209(M-17)mayoritario, 227(M+1)minoritario
- 69
-
B
imagen79 285(M-17)mayoritario, 303(M+1)minoritario
- 70
-
B
imagen80 209(M-17)mayoritario, 227(M+1)minoritario
- 71
-
B
imagen81 211(M-17)mayoritario, 229(M+1)minoritario
- 72
-
B
imagen82 209(M-17)mayoritario, 227(M+1)minoritario
26-11-2014 E04810839
- 73
-
B
imagen83 209(M-17)mayoritario, 227(M+1)minoritario
- 74
-
B
imagen84 257(M-17)mayoritario, 275(M+1)minoritario
- 75
-
B
imagen85 209(M-17)mayoritario, 227(M+1)minoritario
- 76
-
B
imagen86 223(M-17)mayoritario, 241(M+1)minoritario
- 77
-
B
imagen87 223(M-17)mayoritario, 241(M+1)minoritario
- 78
-
B
imagen88 223(M-17)mayoritario, 241(M+1)minoritario
- 79
-
B
imagen89 235(M-17)mayoritario, 253(M+1)minoritario
- 80
-
B
imagen90 235(M-17)mayoritario, 253(M+1)minoritario
- 81
-
B
imagen91 235(M-17)mayoritario, 253(M+1)minoritario
26-11-2014 E04810839
- 82
-
B
imagen92 251(M-17)mayoritario, 269(M+1)minoritario
- 83
-
B
imagen93 235(M-17)mayoritario, 253(M+1)minoritario
- 84
-
B
imagen94 233(M-17)mayoritario, 251(M+1)minoritario
- 85
-
B
imagen95 233(M-17)mayoritario, 251(M+1)minoritario
- 86
-
B
imagen96 275(M-17)mayoritario, 293(M+1)minoritario
- 87
-
B
imagen97 311(M-17)mayoritario, 329(M+1)minoritario
- 88
-
B
imagen98 209(M-17)mayoritario, 227(M+1)minoritario
- 89
-
B
imagen99 434(M-17) mayoritario
- 90
-
B
imagen100 446 (M+1)(23), 428 (100)
26-11-2014 E04810839
- 91
-
B
imagen101 350(M-17)mayoritario, 368(M+1)minoritario
- 92
-
B
imagen102 434(M-17) mayoritario
- 93
-
B
imagen103 346 (M+1)(100), 328 (14)
- 94
-
B
imagen104 511 (9), 256 (M+1)(100), 238(19)
- 95
-
B
imagen105 201 (M+1)(100), 183 (22)
- 96
-
B
imagen106 255 (M+1)(100), 237 (100)
- 97
-
B
imagen107 187 (M+1)(5), 169 (100)
- 98
-
B
imagen108 243(M+1)(5), 225 (71)
- 99
-
B
imagen109 449(5), 243(M+1)(7), 225(100)
26-11-2014
- 100
-
B
imagen110 223(M+23)(3), 183(48)
- 101
-
B
imagen111 223(M+23)(4), 183(10)
- 121
-
F
imagen72 242 (M+1)(100), 224 (19)
- 122
-
F
imagen112 242 (M+1)(100), 224 (9)
- 123
-
F
imagen113 300 (M+1)(11), 282 (100)
- 124
-
F
imagen114 371(M-17)mayoritario, 389(M+1)minoritario
- 125
-
F
imagen72 256 (M+1)(100)
- 126
-
F
imagen115 256 (M+1)(100), 238(8)
- 127
-
F
imagen116 256 (M+1)(100), 238(10)
- 128
-
F
imagen117 210(M-17)(mayoritario), 228 (M+1)(minoritario)
- 129
-
F
imagen118 256 (M+1)(100), 238 (28)
Claims (6)
-
imagen1 imagen2 imagen3 E0481083926-11-2014 -
- 17.
- Combinación farmacéutica según la reivindicación 14, en la que el segundo medicamento es adecuado para el tratamiento de una afección de diabetes.
-
- 18.
- Procedimiento de preparación de un compuesto según la reivindicación 1 que comprende: poner en contacto un compuesto de fórmula (XXX):
imagen4 10 con un compuesto de fórmula (XXXI)imagen5 en la que L comprende un grupo saliente en condiciones adecuadas para proporcionar el compuesto según la 15 reivindicación 1 y en las que R1, R2, R3, R4, R5, X, Z y n son como se definen en la reivindicación 1. - 19. Procedimiento según la reivindicación 18 en el que L es halo.
- 20. Procedimiento según la reivindicación 18 en el que L es cloro. 20
- 21. Procedimiento según la reivindicación 18 que comprende además preparar un compuesto de fórmula XXX, en la que R1 y R2 son cada uno OH, poniendo en contacto ácido y un compuesto de la fórmula XXX, en la que R1 y R2 son cada uno hidroxilo portador de un grupo protector de ácido borónico.43
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51956603P | 2003-11-12 | 2003-11-12 | |
US519566P | 2003-11-12 | ||
US55701104P | 2004-03-25 | 2004-03-25 | |
US557011P | 2004-03-25 | ||
US59297204P | 2004-07-30 | 2004-07-30 | |
US592972P | 2004-07-30 | ||
PCT/US2004/037820 WO2005047297A1 (en) | 2003-11-12 | 2004-11-12 | Heterocyclic boronic acid compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2524916T3 true ES2524916T3 (es) | 2014-12-15 |
Family
ID=34595944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES04810839.3T Active ES2524916T3 (es) | 2003-11-12 | 2004-11-12 | Compuestos heterocíclicos de ácido borónico |
Country Status (21)
Country | Link |
---|---|
US (3) | US7674913B2 (es) |
EP (3) | EP1743676A1 (es) |
JP (3) | JP5435841B2 (es) |
KR (2) | KR20070054762A (es) |
AR (1) | AR046778A1 (es) |
AU (1) | AU2004288831B2 (es) |
BR (1) | BRPI0416444B8 (es) |
CA (1) | CA2545311C (es) |
DK (1) | DK1689757T3 (es) |
EA (1) | EA013684B1 (es) |
ES (1) | ES2524916T3 (es) |
HR (1) | HRP20141155T1 (es) |
IL (1) | IL175550A (es) |
NO (2) | NO337818B1 (es) |
NZ (1) | NZ547752A (es) |
PL (1) | PL1689757T3 (es) |
PT (1) | PT1689757E (es) |
SG (1) | SG134333A1 (es) |
SI (1) | SI1689757T1 (es) |
TW (1) | TWI337078B (es) |
WO (1) | WO2005047297A1 (es) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102558155A (zh) | 2003-01-14 | 2012-07-11 | 阿伦纳药品公司 | 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗 |
AR045047A1 (es) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
US7317109B2 (en) | 2003-11-12 | 2008-01-08 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7767828B2 (en) | 2003-11-12 | 2010-08-03 | Phenomix Corporation | Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
SI1689757T1 (sl) | 2003-11-12 | 2015-01-30 | Sino-Med International Alliance, Inc. | Heterociklične spojine boronske kisline |
US7576121B2 (en) | 2003-11-12 | 2009-08-18 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
MXPA06009589A (es) * | 2004-02-23 | 2007-03-26 | Tufts College | Inhibidores de dipeptidil peptidasa iv par regular el metabolismo de glucosa. |
US20060063719A1 (en) * | 2004-09-21 | 2006-03-23 | Point Therapeutics, Inc. | Methods for treating diabetes |
DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
AU2006246719A1 (en) | 2005-05-19 | 2006-11-23 | Genentech, Inc. | Fibroblast activation protein inhibitor compounds and methods |
US7825139B2 (en) | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
BRPI0612607A2 (pt) * | 2005-07-05 | 2010-12-07 | Tufts College | inibidores de alfa proteìna de ativação de fibroblasto |
MX2008001612A (es) * | 2005-08-01 | 2008-04-04 | Phenomix Corp | Metodos para preparar acidos boronicos heterociclicos y derivados de los mismos. |
WO2007061434A2 (en) * | 2005-11-10 | 2007-05-31 | Nastech Pharmaceutical Company Inc. | A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome |
EP1971614A1 (en) | 2005-11-14 | 2008-09-24 | Probiodrug AG | Cyclopropyl-fused pyrrolidine derivatives as dipeptidyl peptidase iv inhibitors |
JP5165582B2 (ja) * | 2005-12-16 | 2013-03-21 | メルク・シャープ・エンド・ドーム・コーポレイション | ジペプチジルペプチダーゼ−4インヒビターとメトホルミンとを組み合わせた医薬組成物 |
GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
US20090318502A1 (en) * | 2006-03-22 | 2009-12-24 | Intranasal Therapeutics, Inc. | Pharmaceutical Compositions Comprising a Hypoglycemic Agent and Methods of Using Same |
JP2007262017A (ja) * | 2006-03-29 | 2007-10-11 | Ajinomoto Co Inc | ピペコリン酸含有抗糖尿病組成物 |
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
BRPI0709984A2 (pt) | 2006-04-12 | 2011-08-02 | Probiodrug Ag | inibidores de enzima |
CL2007002499A1 (es) * | 2006-08-30 | 2008-03-14 | Phenomix Corp | Sales citrato y tartrato de compuestos derivados de acido pirrolidinilaminoacetilpirrolidinboronico, inhibidores de dpp-iv; metodo de preparacion; forma solida; combinacion farmaceutica, util para el tratamiento de diabetes. |
CL2007002634A1 (es) * | 2006-09-13 | 2008-05-16 | Smithkline Beecham Corp | Uso de una composicion que comprende al menos un polipeptido que tiene actividad de peptido-1 semejante a glucagon (glp-1) como agente hipoglucemiante de larga duracion. |
KR20090077935A (ko) * | 2006-09-29 | 2009-07-16 | 센토코 오르토 바이오테크 인코포레이티드 | 내당능 장애 관련 증상을 예방하거나 치료하기 위한 인간 epo 수용체 작용제, 조성물, 방법 및 용도 |
WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
ATE554085T1 (de) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
WO2008128126A1 (en) * | 2007-04-11 | 2008-10-23 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
US20160331729A9 (en) | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
EP2865670B1 (en) | 2007-04-18 | 2017-01-11 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
EP2326326B1 (en) | 2008-08-15 | 2019-10-09 | Boehringer Ingelheim International GmbH | Dpp-4 inhibitors for use for the treatment of wound healing in diabetic patients |
TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
TWI466672B (zh) | 2009-01-29 | 2015-01-01 | Boehringer Ingelheim Int | 小兒科病人糖尿病之治療 |
AP2011005794A0 (en) | 2009-02-13 | 2011-08-31 | Boehringer Ingelheim Int | Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a furtherantidiabetic agent and uses thereof. |
US20120094894A1 (en) | 2009-02-13 | 2012-04-19 | Boehringer Ingelheim International Gmbh | Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
WO2010107809A2 (en) * | 2009-03-17 | 2010-09-23 | Forest Laboratories Holdings Limited | Methods for preparing dpp-iv inhibitor compounds |
AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
EP2475428B1 (en) | 2009-09-11 | 2015-07-01 | Probiodrug AG | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
MX364651B (es) | 2009-11-27 | 2019-05-03 | Boehringer Ingelheim Int Gmbh Star | Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmacéuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabéticos tipificados genéticamente. |
ES2586231T3 (es) | 2010-03-03 | 2016-10-13 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
CN102791704B (zh) | 2010-03-10 | 2015-11-25 | 前体生物药物股份公司 | 谷氨酰胺酰环化酶(qc, ec 2.3.2.5)的杂环抑制剂 |
CN102286011B (zh) * | 2010-03-16 | 2017-10-03 | 美德(江西)生物科技有限公司 | 吡咯烷硼酸酯二肽基肽酶抑制剂及其药物组合物 |
WO2011113947A1 (en) | 2010-03-18 | 2011-09-22 | Boehringer Ingelheim International Gmbh | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
WO2011127051A1 (en) | 2010-04-06 | 2011-10-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
EP2566469B1 (en) | 2010-05-05 | 2022-12-21 | Boehringer Ingelheim International GmbH | Combination therapy |
EP2585101A1 (en) | 2010-06-24 | 2013-05-01 | Boehringer Ingelheim International GmbH | Diabetes therapy |
US8680136B2 (en) | 2010-08-10 | 2014-03-25 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
US10894787B2 (en) | 2010-09-22 | 2021-01-19 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
JP6189754B2 (ja) | 2011-03-04 | 2017-08-30 | イントレキソン コーポレーション | タンパク質を条件的に発現するベクター |
US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US20140051714A1 (en) | 2011-04-22 | 2014-02-20 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
MX2016016666A (es) | 2014-07-01 | 2017-08-08 | Rempex Pharmaceuticals Inc | Derivados de acido boronico y usos terapeuticos de los mismos. |
US10662205B2 (en) | 2014-11-18 | 2020-05-26 | Qpex Biopharma, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
KR20230151072A (ko) | 2015-01-06 | 2023-10-31 | 아레나 파마슈티칼스, 인크. | S1p1 수용체와 관련된 상태의 치료 방법 |
KR20220070057A (ko) | 2015-03-09 | 2022-05-27 | 인테크린 테라퓨틱스, 아이엔씨. | 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법 |
WO2016149393A1 (en) | 2015-03-17 | 2016-09-22 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
HUE060476T2 (hu) | 2015-06-22 | 2023-03-28 | Arena Pharm Inc | (R)-2-(7-(4-ciklopentil-3-(trifluormetil)benziloxi)-1,2,3,4- tetrahidrociklopenta[B]indol-3-il)ecetsav kristályos L-arginin-sója S1P1 receptorral kapcsolatos rendellenességek esetén való alkalmazásra |
SG10201902424TA (en) | 2015-09-21 | 2019-04-29 | Lumos Pharma Inc | Detecting and treating growth hormone deficiency |
ES2894251T3 (es) * | 2016-06-30 | 2022-02-14 | Qpex Biopharma Inc | Derivados de ácido borónico y usos terapéuticos de los mismos |
WO2018069442A1 (en) | 2016-10-12 | 2018-04-19 | University Of Copenhagen | Peptide dual agonists of gipr and glp2r |
EP3582772A1 (en) | 2017-02-16 | 2019-12-25 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
AU2018249822A1 (en) | 2017-04-03 | 2019-10-31 | Coherus Biosciences Inc. | PPArgamma agonist for treatment of progressive supranuclear palsy |
PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
WO2019075084A1 (en) | 2017-10-11 | 2019-04-18 | Qpex Biopharma, Inc. | BORONIC ACID DERIVATIVES AND SYNTHESIS THEREOF |
WO2023192665A2 (en) * | 2022-04-01 | 2023-10-05 | Praxis Precision Medicines, Inc. | T-type calcium channel modulators and methods of use thereof |
Family Cites Families (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US560246A (en) * | 1896-05-19 | Pneumatic tire | ||
US3674836A (en) | 1968-05-21 | 1972-07-04 | Parke Davis & Co | 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof |
US4027009A (en) | 1973-06-11 | 1977-05-31 | Merck & Co., Inc. | Compositions and methods for depressing blood serum cholesterol |
JPS5612114B2 (es) | 1974-06-07 | 1981-03-18 | ||
NO154918C (no) | 1977-08-27 | 1987-01-14 | Bayer Ag | Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin. |
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
DE2951135A1 (de) | 1979-12-19 | 1981-06-25 | Hoechst Ag, 6230 Frankfurt | Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
MX7065E (es) | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
US4450171A (en) | 1980-08-05 | 1984-05-22 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US4448784A (en) | 1982-04-12 | 1984-05-15 | Hoechst-Roussel Pharmaceuticals, Inc. | 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
JPS6051189A (ja) | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | チアゾリジン誘導体およびその製造法 |
DE3543999A1 (de) | 1985-12-13 | 1987-06-19 | Bayer Ag | Hochreine acarbose |
US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US4759923A (en) | 1987-06-25 | 1988-07-26 | Hercules Incorporated | Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives |
JP2569746B2 (ja) | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
US4935493A (en) * | 1987-10-06 | 1990-06-19 | E. I. Du Pont De Nemours And Company | Protease inhibitors |
US4924024A (en) | 1988-01-11 | 1990-05-08 | E. R. Squibb & Sons, Inc. | Phosphorus-containing squalene synthetase inhibitors, new intermediates and method |
US4871721A (en) | 1988-01-11 | 1989-10-03 | E. R. Squibb & Sons, Inc. | Phosphorus-containing squalene synthetase inhibitors |
NO177005C (no) | 1988-01-20 | 1995-07-05 | Bayer Ag | Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
ES2099158T3 (es) * | 1990-04-14 | 1997-05-16 | New England Medical Center Inc | Tratamiento del rechazo de trasplantes o de enfermedades autoinmunitarias y complejo de la formula general x-pro-y-boropro asociada al mismo. |
US5462928A (en) | 1990-04-14 | 1995-10-31 | New England Medical Center Hospitals, Inc. | Inhibitors of dipeptidyl-aminopeptidase type IV |
US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
JPH07504158A (ja) | 1991-10-22 | 1995-05-11 | ニュー イングランド メディカル センター ホスピタルズ インク | ジペプチジル−アミノペプチダーゼiv型のインヒビタ |
MX9206628A (es) * | 1991-11-22 | 1993-05-01 | Boehringer Ingelheim Pharma | Ester de prolinaboronato y metodo para su preparacion. |
US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
DK36392D0 (da) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
US5447954A (en) | 1992-05-05 | 1995-09-05 | Smithkline Beecham P.L.C. | Phenylderivate as inhibitors of ATP citrate lyase |
US5712396A (en) | 1992-10-28 | 1998-01-27 | Magnin; David R. | α-phosphonosulfonate squalene synthetase inhibitors |
US5594016A (en) | 1992-12-28 | 1997-01-14 | Mitsubishi Chemical Corporation | Naphthalene derivatives |
WO1994016693A1 (en) | 1993-01-19 | 1994-08-04 | Warner-Lambert Company | Stable oral ci-981 formulation and process of preparing same |
US5346701A (en) | 1993-02-22 | 1994-09-13 | Theratech, Inc. | Transmucosal delivery of macromolecular drugs |
US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
WO1995011689A1 (en) * | 1993-10-29 | 1995-05-04 | Trustees Of Tufts College | Use of inhibitors of dipeptidyl-aminopeptidase to block entry of hiv into cells |
IL111785A0 (en) * | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
US5776983A (en) | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
US5488064A (en) | 1994-05-02 | 1996-01-30 | Bristol-Myers Squibb Company | Benzo 1,3 dioxole derivatives |
US5385929A (en) | 1994-05-04 | 1995-01-31 | Warner-Lambert Company | [(Hydroxyphenylamino) carbonyl] pyrroles |
US5574017A (en) | 1994-07-05 | 1996-11-12 | Gutheil; William G. | Antibacterial agents |
US5491134A (en) | 1994-09-16 | 1996-02-13 | Bristol-Myers Squibb Company | Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives |
US5541204A (en) | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
US5620997A (en) | 1995-05-31 | 1997-04-15 | Warner-Lambert Company | Isothiazolones |
DE69522718T2 (de) | 1995-06-06 | 2002-02-07 | Pfizer | Substituierte n-(indol-2-carbonyl)-amide und derivate als glycogen phosphorylase inhibitoren |
DK0832065T3 (da) | 1995-06-06 | 2001-11-19 | Pfizer | Substituerede N-(indol-2-carbonyl)glycinamider og derivater som glycogenphosphorylaseinhibitorer |
WO1997012613A1 (en) | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
ATE344279T1 (de) | 1995-12-13 | 2006-11-15 | Univ California | Kristalle der mit einem ligand komplexierten ligandenbindedomäne des schilddrüsenhormonrezeptors |
US5770615A (en) | 1996-04-04 | 1998-06-23 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
DE19616486C5 (de) | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
US5962440A (en) | 1996-05-09 | 1999-10-05 | Bristol-Myers Squibb Company | Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method |
US5885983A (en) | 1996-05-10 | 1999-03-23 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
US5827875A (en) | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
US5965532A (en) | 1996-06-28 | 1999-10-12 | Trustees Of Tufts College | Multivalent compounds for crosslinking receptors and uses thereof |
HRP970330B1 (en) | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
US6011155A (en) | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
US5952322A (en) | 1996-12-05 | 1999-09-14 | Pfizer Inc. | Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors |
US5952301A (en) | 1996-12-10 | 1999-09-14 | 1149336 Ontario Inc. | Compositions and methods for enhancing intestinal function |
US5760246A (en) | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
US6100234A (en) * | 1997-05-07 | 2000-08-08 | Tufts University | Treatment of HIV |
US6040145A (en) | 1997-05-07 | 2000-03-21 | Tufts University | Potentiation of the immune response |
GB9713739D0 (en) | 1997-06-27 | 1997-09-03 | Karobio Ab | Thyroid receptor ligands |
KR100247563B1 (ko) | 1997-07-16 | 2000-04-01 | 박영구 | 키랄3,4-에폭시부티르산및이의염의제조방법 |
ATE357509T1 (de) | 1997-09-29 | 2007-04-15 | Point Therapeutics Inc | Stimulierung von hämatopoietischen zellen im vitro |
UA57811C2 (uk) | 1997-11-21 | 2003-07-15 | Пфайзер Продактс Інк. | Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності |
EP2433623A1 (en) | 1998-02-02 | 2012-03-28 | Trustees Of Tufts College | Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism |
US5998463A (en) | 1998-02-27 | 1999-12-07 | Pfizer Inc | Glycogen phosphorylase inhibitors |
EP1056729B1 (en) | 1998-02-27 | 2004-12-29 | Pfizer Products Inc. | N-[(substituted five-membered di- or triaza diunsaturated ring)carbonyl]guanidine derivatives for the treatment of ischemia |
EP1075266A1 (en) | 1998-05-04 | 2001-02-14 | Point Therapeutics, Inc. | Hematopoietic stimulation |
KR100704814B1 (ko) | 1998-06-05 | 2007-04-10 | 포인트 써러퓨틱스, 인크. | 시클릭 보로프롤린 화합물 |
EP0978279A1 (en) | 1998-08-07 | 2000-02-09 | Pfizer Products Inc. | Inhibitors of human glycogen phosphorylase |
CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
US6462091B1 (en) | 1998-12-23 | 2002-10-08 | G.D. Searle & Co. | Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications |
GB9828442D0 (en) | 1998-12-24 | 1999-02-17 | Karobio Ab | Novel thyroid receptor ligands and method II |
EP1150674A1 (en) | 1999-02-12 | 2001-11-07 | Novo Nordisk A/S | Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation |
US6518292B1 (en) | 1999-03-12 | 2003-02-11 | Bristol-Myers Squibb Co. | Heterocyclic aromatic compounds usefuls as growth hormone secretagogues |
DK1041068T3 (da) | 1999-04-01 | 2004-05-10 | Pfizer Prod Inc | Compounds for treating and preventing diabetic complications |
US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
US6172081B1 (en) | 1999-06-24 | 2001-01-09 | Novartis Ag | Tetrahydroisoquinoline 3-carboxamide derivatives |
US6107317A (en) | 1999-06-24 | 2000-08-22 | Novartis Ag | N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
US6110949A (en) | 1999-06-24 | 2000-08-29 | Novartis Ag | N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
US6617340B1 (en) | 1999-07-29 | 2003-09-09 | Novartis Ag | N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
US6380398B2 (en) | 2000-01-04 | 2002-04-30 | Novo Nordisk A/S | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
US6432969B1 (en) | 2000-06-13 | 2002-08-13 | Novartis Ag | N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
EP1487471A4 (en) * | 2001-11-26 | 2010-03-10 | Tufts College | METHOD FOR TREATING AUTOIMMUNE DISEASES AND ASSOCIATED REAGENTS |
JP4771661B2 (ja) * | 2001-11-26 | 2011-09-14 | トラスティーズ オブ タフツ カレッジ | Post−プロリン開裂酵素の擬ペプチド性阻害剤 |
CA2491466A1 (en) | 2002-07-09 | 2004-01-15 | Sharlene Adams | Methods and compositions relating to isoleucine boroproline compounds |
US6894784B2 (en) | 2002-11-05 | 2005-05-17 | O. I. Corporation, Inc. | Foam detector and disruptor |
SI1689757T1 (sl) * | 2003-11-12 | 2015-01-30 | Sino-Med International Alliance, Inc. | Heterociklične spojine boronske kisline |
US7767828B2 (en) | 2003-11-12 | 2010-08-03 | Phenomix Corporation | Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7317109B2 (en) | 2003-11-12 | 2008-01-08 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7576121B2 (en) | 2003-11-12 | 2009-08-18 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
WO2005075426A1 (en) | 2004-02-03 | 2005-08-18 | Glenmark Pharmaceuticals Ltd. | Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof |
AU2005293266B2 (en) | 2004-10-12 | 2011-09-29 | Glenmark Pharmaceuticals S.A. | Novel dipeptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and process for their preparation |
US7825139B2 (en) | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
JP2008220344A (ja) | 2007-03-09 | 2008-09-25 | Tekkuten:Kk | 農作物及び畜産物の防病並びに育成促進方法 |
-
2004
- 2004-11-12 SI SI200432201T patent/SI1689757T1/sl unknown
- 2004-11-12 EA EA200600935A patent/EA013684B1/ru not_active IP Right Cessation
- 2004-11-12 TW TW093134766A patent/TWI337078B/zh active
- 2004-11-12 BR BRPI0416444A patent/BRPI0416444B8/pt active IP Right Grant
- 2004-11-12 EP EP06015708A patent/EP1743676A1/en not_active Withdrawn
- 2004-11-12 US US10/514,575 patent/US7674913B2/en active Active - Reinstated
- 2004-11-12 NZ NZ547752A patent/NZ547752A/en active IP Right Revival
- 2004-11-12 KR KR1020077011094A patent/KR20070054762A/ko not_active Application Discontinuation
- 2004-11-12 CA CA2545311A patent/CA2545311C/en active Active
- 2004-11-12 DK DK04810839.3T patent/DK1689757T3/en active
- 2004-11-12 AR ARP040104198A patent/AR046778A1/es active IP Right Grant
- 2004-11-12 JP JP2006539906A patent/JP5435841B2/ja active Active
- 2004-11-12 AU AU2004288831A patent/AU2004288831B2/en not_active Ceased
- 2004-11-12 SG SG200705459-6A patent/SG134333A1/en unknown
- 2004-11-12 EP EP08013650.0A patent/EP1997533B8/en active Active
- 2004-11-12 PT PT48108393T patent/PT1689757E/pt unknown
- 2004-11-12 PL PL04810839T patent/PL1689757T3/pl unknown
- 2004-11-12 EP EP04810839.3A patent/EP1689757B1/en active Active
- 2004-11-12 ES ES04810839.3T patent/ES2524916T3/es active Active
- 2004-11-12 WO PCT/US2004/037820 patent/WO2005047297A1/en active Application Filing
- 2004-11-12 KR KR1020067011419A patent/KR100918322B1/ko active IP Right Grant
-
2006
- 2006-05-10 IL IL175550A patent/IL175550A/en active IP Right Grant
- 2006-06-12 NO NO20062711A patent/NO337818B1/no unknown
- 2006-11-06 US US11/556,944 patent/US20070185061A1/en not_active Abandoned
-
2007
- 2007-08-01 JP JP2007201372A patent/JP2008019261A/ja not_active Withdrawn
-
2008
- 2008-08-28 JP JP2008220344A patent/JP5398199B2/ja active Active
-
2010
- 2010-01-22 US US12/692,276 patent/US8415295B2/en active Active
-
2014
- 2014-11-27 HR HRP20141155TT patent/HRP20141155T1/hr unknown
-
2016
- 2016-04-15 NO NO20160635A patent/NO340063B1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2524916T3 (es) | Compuestos heterocíclicos de ácido borónico | |
US9975904B2 (en) | Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes | |
JP5586484B2 (ja) | ピロリジン誘導体 | |
US10377744B2 (en) | Potent soluble epdxide hydrolase inhibitors | |
JP6236067B2 (ja) | RORγ活性を阻害し疾患を治療するための二環式スルホン化合物 | |
US11236058B2 (en) | Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia | |
ES2552051T3 (es) | Derivados de acrilamido útiles como inhibidores de la transición de la permeabilidad mitocondrial | |
US20070093492A1 (en) | Pyrrolidine derivatives | |
US20060148844A1 (en) | Pharmaceutical composition for treatment of disease due to vascular constriction or vasodilation | |
JP2009541484A (ja) | 5ht6モジュレーターおよびコリンエステラーゼインヒビターを含む組み合わせ | |
JP2010519328A (ja) | H−pgdsの阻害剤としてのニコチンアミド誘導体およびプロスタグランジンd2が媒介する疾患の治療のためのそれらの使用 | |
US20060223884A1 (en) | Compounds and compositions for use in the prevention and treatment of obesity and related syndromes | |
TW202206424A (zh) | Bcl—2蛋白抑制劑 | |
WO2017117556A1 (en) | Positive allosteric modulators of the glp-1 receptor | |
JP5666468B2 (ja) | システインプロテアーゼ阻害剤 | |
WO2006095822A1 (ja) | スルホンアミド化合物およびその医薬 | |
US20090281161A1 (en) | Organic Compounds | |
AU2007260298A1 (en) | Pyrrolidine compounds as renin inhibitors | |
WO2019195493A2 (en) | Substituted 2-aminobenzimidazoles analogs as antibiofilm agents |